ArticleFrontiers in oncology2020

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Alexandra Lindsey Zune Djomkam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.